Bhuvin Buddhdev, MD
Pulmonary Disease · Phoenix, AZNPI 1881907681
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by United Therapeutics Corporation at 55.6% of the total. 2025 is the largest year on record at $14,114, more than ten times the $326 reported in 2019. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $161.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$20K
- Actelion Pharmaceuticals US, Inc.$11K
- Pfizer$1K
- Bayer$535
- Paragonix Technologies, Inc.$439
- AbbVie$428
- plus $2K from 24 others
Across 26 payments — averaging $6381.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$166K
What the payments were for
- Consulting fees$20,91558%
- Travel & lodging$3,99211%
- Food & beverage$10,85130%
- Education$2691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 82 | $20,047 |
| Actelion Pharmaceuticals US, Inc. | 61 | $11,304 |
| Pfizer | 1 | $1,000 |
| Bayer | 5 | $535 |
| Paragonix Technologies, Inc. | 2 | $439 |
| AbbVie(2 entities) | 5 | $428 |
| Merck | 10 | $412 |
| Johnson & Johnson(2 entities) | 3 | $232 |
| Astellas Pharma US Inc | 5 | $219 |
| Insmed, Inc. | 9 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $189 |
| Abbott | 1 | $179 |
| Abiomed | 1 | $140 |
| Boehringer Ingelheim | 5 | $123 |
| Sandoz | 4 | $73 |
| Sanofi | 4 | $68 |
| AstraZeneca | 4 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Medtronic | 1 | $46 |
| GSK | 2 | $38 |
| Shionogi Inc | 2 | $34 |
| Biomerieux Inc | 1 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
| Vifor Pharma, Inc. | 1 | $24 |
| Invivyd Inc | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Breas Medical, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,027 in reported general payments places this provider in the 90th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrevymisLetermovir | 71 | $595,240 |
| OpsumitMacitentan | 46 | $580,720 |
| Tyvaso DpiTreprostinil | 22 | $502,335 |
| OfevNintedanib Esylate | 35 | $484,270 |
| CresembaIsavuconazonium Sulfate | 58 | $413,191 |
| AdempasRiociguat | 14 | $189,394 |
| Pirfenidone | 41 | $105,474 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $81,458 |
| EliquisApixaban | 77 | $73,773 |
| Itraconazole | 111 | $68,168 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $67,307 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $44,258 |
| Valganciclovir Hcl | 103 | $39,321 |
| Posaconazole | 56 | $39,195 |
| Atovaquone | 45 | $29,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckPrevymis | $412 | $595,24071 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $11,304 | $580,72046 claims |
| Boehringer IngelheimOfev | $123 | $484,27035 claims |
| Astellas Pharma US IncCresemba | $219 | $413,19158 claims |
| BayerAdempas | $535 | $189,39414 claims |
| PfizerEliquis | $1,000 | $73,77377 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $189 | $44,25827 claims |
| GSKTrelegy Ellipta | $38 | $24,52523 claims |
| AstraZenecaLokelma, Breztri Aerosphere | $62 | $18,12122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.